Evaluation of weekly epirubicin-paclitaxel (EP) cardiotoxicity with serum troponin-t and myoglobin and echocardiography in advanced breast cancer (ABC).

C. Nisticó,E. Bria,A. Carpino,G. Vitelli,F. Cuppone,F. Izzo,F. Tropea,B. Vanni,P. Astorre,E. Terzoli

DOI: https://doi.org/10.1200/JCO.2004.22.90140.775

IF: 45.3

2004-07-15

Journal of Clinical Oncology

Abstract:775 Background: Troponin (TnT) and myoglobin (M) seem to be involved in myocardial damage; increasing serum level of TnT has been recently related to cumulative antracyclines exposure. Left ventricular ejection fraction (L-FEV) seems accurate in monitoring systolic function for cardiac damage measurement; its decreasing is recently entered as parameter of toxicity criteria of chemotherapeutics (CTC 3.0). E/A ratio is useful to assay diastolic function to predict systolic failure. METHODS From January 2002, 20 pts with untreated ABC underwent E: 25 mg/m2/week and P: 80 mg/m2/week with G-CSF support days 2,4, for 24 consecutive weeks. We had checked TnT, myoglobin, ALT, AST, LDH, CPK, CK-MB, PcR (protein-C-reactive) lab serum assay immediately before and 4 hours after E administration, every week. Pts underwent EKG and echocardiography (Eco) (L-FEV and E/A ratio measurement) at week n° 0, 8, 16 and 24. RESULTS Number of courses was 352 (median: 18, range: 4-24). E median achieved dose: 550 mg/m2, range 100-600; E median dose intensity (DI mg/m2/week): 22,95 (91,8%), range 15,6-25. P median achieved dose: 1760 mg/m2; P median dose intensity (DI mg/m2/week): 73,46 (91,8%), range 50-80. TnT never went over nrv (normal range values); 1 patient experienced increasing without any clinical/instrumental sign of cardiotoxicity. M never significantly increased except for a patient undergone several paracentesys. CK-MB and PcR never moved outside nrv. ALT, AST, LDH always within nrv except for pts with liver metastases. No symptomatic cardiac event were recorded; neither L-FEV and E/A significant decreasing occurred. In 55 Eco examinations at week 0, 8, 16, 24, median L-FEV (%) and median E/A were respectively: 66%, 67%, 64,5%, 65,5%, and 1.1, 1.11, 1,015, 1,1. CONCLUSIONS No TnT/M and L-FEV/E/A alteration were seen in our subset of ABC non-symptomatic pts during weekly chemotherapy with E and P. No acute cardiac toxicity were record. We're waiting a longer follow-up to understand if the combination of these serum and instrumental parameters are useful in monitoring chronic cardiac damage. No significant financial relationships to disclose.